Out of stock

This item is currently unavailable

Out of stock for 29 days. Get on the list — one email the moment it's back.

Out of stock 29 days · last price £204

Bridging the Gap: In This Era of Cancer Immunotherapy (Cancer Etiology, Diagnosis and Treatments)

Amazon

Price History & Forecast

Grey patches = out of stock. Cheaper = lower on the chart. Hover for exact prices.

Last 79 days · 79 data points (no recent data)

Historical
Generating forecast…
£203.99 £193.79 £197.87 £201.95 £206.03 £210.11 £214.19 11 August 2026 30 August 2026 19 September 2026 08 October 2026 28 October 2026
View at Amazon ↗
Out of stock

Price data last checked 12 day(s) ago - will refresh soon

NEW HERE?

Amazon shows you one price. We show you all of them.

Tosheroon watches Amazon prices so you don't have to. Every product on Amazon has a price history — we make it visible. Set the price you'd actually pay, and we'll email you the second it gets there. No app, no account, one email.

WHAT'S ON THIS PAGE

↑ Price chart
when this has been cheap or pricey
↑ Forecast
where the price is heading next
↓ Statistics
all-time high & low, recent range
↑ Price alert
name your number, we'll email you

Price Distribution

Price distribution over 79 days • 1 price levels

Days at Price
79 days 0 20 40 59 79 £204 Days at Price

Price Analysis

Most common price: £204 (79 days, 100.0%)

Price range: £204 - £204

Price levels: 1 different prices over 79 days

Description

Recognizing rare diseases' impracticability of having extensive clinical trials necessary for regulatory approval, the US Orphan Drug Act appropriately facilitates the commercialization of "orphan drugs". However, even common cancers also have rather specific but uncommon clinical situations for which extensive clinical trials are hardly practicable. Moreover, although such very costly and extensive trials often depend on industry support, uncommon situations are unattractive. Eventually, many specific treatments for designated clinical oncology situations often lack regulatory approvals merely because of suboptimal trial data. Now, this EBM (evidence-based medicine) book by expert authors with first-hand clinical experience is about off-label but acceptable treatment options. The attempt is to patch up the low response rates and considerable adverse events of novel immunotherapy. Currently, without any such off-label treatments, some cancer patients may well be left out in the cold. Although off-label treatments lack regulatory approval, they are backed by EBM and have good safety profiles. It's inappropriate to announce "nothing else can be done" merely because all approved options have already been exhausted. In expert hands, despite the "on compassionate grounds" proviso, the safety profiles of such off-label prescriptions may even compare favorably with orthodox chemotherapy given at top doses.

Product Specifications

Format
hardcover
Domain
Amazon UK
Release Date
11 August 2021
Listed Since
30 July 2021

Barcode

No barcode data available

Similar Products You Might Like

Experimental and Applied Immunotherapy
81% match

Experimental and Applied Immunotherapy

Humana

£140.31 12 Oct 2026
Alternative and Complementary Therapies for Cancer: Integrative Approaches and Discovery of Conventional Drugs
81% match

Alternative and Complementary Therapies for Cancer: Integrative Approaches and Discovery of Conventional Drugs

Springer

£77.90 21 Oct 2026
Experimental and Applied Immunotherapy
81% match

Experimental and Applied Immunotherapy

Humana

£149.98 26 Oct 2026
Non-Small Cell Lung Cancer: New Research (Cancer Etiology, Diagnosis and Treatments)
81% match

Non-Small Cell Lung Cancer: New Research (Cancer Etiology, Diagnosis and Treatments)

£63.27 23 Oct 2026
Oncologic Emergency Medicine: Principles and Practice
80% match

Oncologic Emergency Medicine: Principles and Practice

Springer

£259.83 26 Oct 2026
Advances in Brain Tumor Therapy: From Molecular Mechanisms to Clinical Practice
80% match

Advances in Brain Tumor Therapy: From Molecular Mechanisms to Clinical Practice

Elsevier

£137.99 23 Oct 2026
Immuno-Oncology: From Bench to Bedside
80% match

Immuno-Oncology: From Bench to Bedside

CREATESPACE

£82.80 30 Oct 2026
Emergency conditions in oncology: Emergency conditions in patients with malignant tumors and intensive care
80% match

Emergency conditions in oncology: Emergency conditions in patients with malignant tumors and intensive care

£57.91 30 Oct 2026
Gene and Cellular Immunotherapy for Cancer (Cancer Drug Discovery and Development)
80% match

Gene and Cellular Immunotherapy for Cancer (Cancer Drug Discovery and Development)

Humana

£113.77 30 Oct 2026
Immunotherapy for Gastrointestinal Cancer
80% match

Immunotherapy for Gastrointestinal Cancer

Springer

£99.11 27 Oct 2026
Immunotherapy for Pediatric Malignancies
80% match

Immunotherapy for Pediatric Malignancies

Springer

£113.90 26 Oct 2026
Advances in Tumor Immunology and Immunotherapy (Current Cancer Research)
79% match

Advances in Tumor Immunology and Immunotherapy (Current Cancer Research)

Springer

£112.59 28 Oct 2026
Advances in Tumor Immunology and Immunotherapy (Current Cancer Research)
79% match

Advances in Tumor Immunology and Immunotherapy (Current Cancer Research)

Springer

£113.69 24 Oct 2026
Brain Tumor Immunotherapy
79% match

Brain Tumor Immunotherapy

Humana

£128.74 26 Oct 2026
Cancer Clinical Trials: Proactive Strategies: 132 (Cancer Treatment and Research, 132)
79% match

Cancer Clinical Trials: Proactive Strategies: 132 (Cancer Treatment and Research, 132)

Springer

£113.76 22 Oct 2026
Nanotechnology in Brain Tumor Treatment: Unveiling Molecular Mechanisms and Pioneering Therapies
79% match

Nanotechnology in Brain Tumor Treatment: Unveiling Molecular Mechanisms and Pioneering Therapies

Elsevier

£137.99 22 Oct 2026
Basic and Clinical Tumor Immunology: 14 (Cancer Treatment and Research, 14)
79% match

Basic and Clinical Tumor Immunology: 14 (Cancer Treatment and Research, 14)

Springer

£165.38 25 Oct 2026
Nutraceuticals and Cancer
79% match

Nutraceuticals and Cancer

Springer

£113.76 23 Oct 2026
Integrative Medicine for Breast Cancer: An Evidence-Based Assessment
79% match

Integrative Medicine for Breast Cancer: An Evidence-Based Assessment

Springer

£65.61 22 Oct 2026
79% match

Biosimilars in Cancer

Elsevier

£153.99 21 Oct 2026
Cancer Immunotherapy at the Crossroads: How Tumors Evade Immunity and What Can Be Done (Current Clinical Oncology)
79% match

Cancer Immunotherapy at the Crossroads: How Tumors Evade Immunity and What Can Be Done (Current Clinical Oncology)

Humana

£113.76 23 Oct 2026
Text Book on Clinical Haematology-Oncology
79% match

Text Book on Clinical Haematology-Oncology

Scholars' Press

£70.03 09 Sep 2026
Immunotherapy of Cancer: Methods and Protocols: 651 (Methods in Molecular Biology, 651)
79% match

Immunotherapy of Cancer: Methods and Protocols: 651 (Methods in Molecular Biology, 651)

Humana

£113.61 22 Oct 2026
Cancer Immunotherapy: Paradigms, Practice and Promise
79% match

Cancer Immunotherapy: Paradigms, Practice and Promise

Springer

£114.89 23 Oct 2026